Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C)

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2030-2040

  Salem, Mohamed L ^a,b   Díaz Montero, C Marcela ^a   Al Khami, Amir A ^a,b   El Naggar, Sabry A ^a,b   Naga, Osama ^a   Montero, Alberto J ^a   Khafagy, Ahmed ^c   Cole, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Tanta University   (Egypt)

^c Suez Canal University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; GLYCOPROTEIN GP 100; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST; CANCER VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON INDUCING AGENT; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TLR3 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; TRANSPLANTATION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON INDUCERS; LYMPHOPENIA; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; POLY I-C; TOLL-LIKE RECEPTOR 3; TRANSPLANTATION CONDITIONING;

EID: 61449258305     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801829     Document Type: Article

References (55)

1. Wrzesinski, C., and N. P. Restifo. 2005. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 17: 195-201.
2. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
3. Paulos, C. M., C. Wrzesinski, A. Kaiser, C. S. Hinrichs, M. Chieppa, L. Cassard, D. C. Palmer, A. Boni, P. Muranski, Z. Yu, et al. 2007. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117: 2197-2204.
4. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501.
5. Rosenberg, S. A., J. C. Yang, P. F. Robbins, J. R. Wunderlich, P. Hwu, R. M. Sherry, D. J. Schwartzentruber, S. L. Topalian, N. P. Restifo, A. Filie, R. Chang, and M. E. Dudley. 2003. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 26: 385-393.
6. Protheroe, A. S., C. Pickard, P. W. Johnson, T. Craddock, J. Shefta, K. Short, F. Lancaster, P. J. Selby, J. Henwood, and A. W. Boylston. 2000. Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. Br. J. Haematol. 111: 766-773.
7. Klebanoff, C. A., H. T. Khong, P. A. Antony, D. C. Palmer, and N. P. Restifo. 2005. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26: 111-117.
8. Bracci, L., F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, and E. Proietti. 2007. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13: 644-653.
9. Schiavoni, G., F. Mattei, T. Di Pucchio, S. M. Santini, L. Bracci, F. Belardelli, and E. Proietti. 2000. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
10. Awwad, M., and R. J. North. 1988. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T- cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65: 87-92.
11. Hoover, S. K., S. K. Barrett, T. M. Turk, T. C. Lee, and H. D. Bear. 1990. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother. 31: 121-127.
12. Ikezawa, Y., M. Nakazawa, C. Tamura, K. Takahashi, M. Minami, and Z. Ikezawa. 2005. Cyclophosphamide decreases the number, percentage and the function of CD25(+) CD4(+) regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 39: 105-112.
13. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
14. Salem, M. L., A. N. Kadima, S. A. El-Naggar, M. P. Rubinstein, Y. Chen, W. E. Gillanders, and D. J. Cole. 2007. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30: 40-53.
15. Mihalyo, M. A., A. D. Doody, J. P. McAleer, E. C. Nowak, M. Long, Y. Yang, and A. J. Adler. 2004. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J. Immunol. 172: 5338-5345.
16. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101: 429-441.
17. Lou, Y., G. Wang, G. Lizee, G. J. Kim, S. E. Finkelstein, C. Feng, N. P. Restifo, and P. Hwu. 2004. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64: 6783-6790.
18. Limpens, J., M. Van Meijer, H. M. Van Santen, W. T. Germeraad, K. Hoeben-Schornagel, M. Breel, R. J. Scheper, and G. Kraal. 1991. Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative. Immunology 73: 255-263.
19. Phipps, R. P., T. E. Mandel, C. T. Schnizlein, and J. G. Tew. 1984. Anamnestic responses induced by antigen persisting on follicular dendritic cells from cyclophosphamide-treated mice. Immunology 51: 387-397.
20. Salem, M. L., A. N. Kadima, D. J. Cole, and W. E. Gillanders. 2005. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28: 220-228.
21. Kato, M., T. K. Neil, D. B. Fearnley, A. D. McLellan, S. Vuckovic, and D. N. Hart. 2000. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int. Immunol. 12: 1511-1519.
22. Salem, M. L., A. N. Kadima, Y. Zhou, C. L. Nguyen, M. P. Rubinstein, M. Demcheva, J. N. Vournakis, D. J. Cole, and W. E. Gillanders. 2004. Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J. Immunol. 172: 5159-5167.
23. Pelaez, B., J. A. Campillo, J. A. Lopez-Asenjo, and J. L. Subiza. 2001. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J. Immunol. 166: 6608-6615.
24. Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, et al. 2002. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
25. Lutsiak, M. E., R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, and H. Sabzevari. 2005. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.
26. O'Keeffe, M., H. Hochrein, D. Vremec, B. Scott, P. Hertzog, L. Tatarczuch, and K. Shortman. 2003. Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood 101: 1453-1459.
27. Suto, A., H. Nakajima, N. Tokumasa, H. Takatori, S. Kagami, K. Suzuki, and I. Iwamoto. 2005. Murine plasmacytoid dendritic cells produce IFN-γ upon IL-4 stimulation. J. Immunol. 175: 5681-5689.
28. Adachi, Y., J. Toki, K. Ikebukuro, M. Tomita, H. Kaneda, A. Tanabe, L. Jun, K. Minamino, Y. Suzuki, S. Taketani, and S. Ikehara. 2002. Immature dendritic cells (CD11c+ CD3- B220- cells) present in mouse peripheral blood. Immunobiology 206: 354-367.
29. Paulos, C. M., A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. 2007. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. 13: 5280-5289.
30. Sapoznikov, A., J. A. Fischer, T. Zaft, R. Krauthgamer, A. Dzionek, and S. Jung. 2007. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J. Exp. Med. 204: 1923-1933.
31. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170: 4102-4110.
32. Lore, K., M. R. Betts, J. M. Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto, M. Roederer, R. A. Seder, and R. A. Koup. 2003. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 171: 4320-4328.
33. Ida, J. A., N. Shrestha, S. Desai, S. Pahwa, W. A. Hanekom, and P. A. Haslett. 2006. A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J. Immunol. Methods 310: 86-99.
34. Prins, R. M., N. Craft, K. W. Bruhn, H. Khan-Farooqi, R. C. Koya, R. Stripecke, J. F. Miller, and L. M. Liau. 2006. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176: 157-164.
35. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immun. 6: 769-776.
36. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
37. Doxsee, C. L., T. R. Riter, M. J. Reiter, S. J. Gibson, J. P. Vasilakos, and R. M. Kedl. 2003. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-α production in CD11c+CD11b+ CD8- dendritic cells. J. Immunol. 171: 1156-1163.
38. Salem, M. L., S. A. El-Naggar, A. Kadima, W. E. Gillanders, and D. J. Cole. 2006. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24: 5119-5132.
39. Salem, M. L., A. N. Kadima, S. EL-Naggar, M. P. Rubinstein, W. E. Gillanders, and D. J. Cole. 2007. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8 T cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30: 40-53.
40. Sánchez-Sánchez, N., L. Riol-Blanco, and and J. L. Rodríguez-Fernández. 2006. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176: 5153-5159.
41. Carbone, F. R., G. T. Belz, and W. R. Heath. 2004. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 25: 655-658.
42. Vuckovic, S., M. Kim, D. Khalil, C. J. Turtle, G. V. Crosbie, N. Williams, L. Brown, K. Williams, C. Kelly, P. Stravos, et al. 2003. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 101: 2314-2317.
43. Gazitt, Y., C. Akay, and C. Thomas, 3rd. 2006. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev. 15: 269-277.
44. Radcliff, F. J., D. A. Caruso, C. Koina, M. J. Riordan, A. W. Roberts, M. L. Tang, C. M. Baum, S. L. Woulfe, and D. M. Ashley. 2002. Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. Br. J. Haematol. 119: 204-211.
45. Liu, K., C. Waskow, X. Liu, K. Yao, J. Hoh, and M. Nussenzweig. 2007. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat. Immunol. 8: 578-583.
46. Kabashima, K., T. A. Banks, K. M. Ansel, T. T. Lu, C. F. Ware, and J. G. Cyster. 2005. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 22: 439-450.
47. Wang, L. X., R. Li, G. Yang, M. Lim, A. O'Hara, Y. Chu, B. A. Fox, N. P. Restifo, W. J. Urba, and H. M. Hu. 2005. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 65: 10569-10577.
48. Torihata, H., F. Ishikawa, Y. Okada, Y. Tanaka, T. Uchida, T. Suguro, and T. Kakiuchi. 2004. Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells. Immunology 112: 219-227.
49. Zhang, Y., J. P. Louboutin, J. Zhu, A. J. Rivera, and S. G. Emerson. 2002. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J. Clin. Invest. 109: 1335-1344.
50. Klebanoff, C. A., L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A. R. Cardones, S. E. Finkelstein, D. C. Palmer, P. A. Antony, S. T. Hwang, S. A. Rosenberg, T. A. Waldmann, and N. P. Restifo. 2005. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576.
51. Merad, M., T. Sugie, E. G. Engleman, and L. Fong. 2002. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99: 1676-1682.
52. Cornet, S., J. Menez-Jamet, F. Lemonnier, K. Kosmatopoulos, and I. Miconnet. 2006. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. Vaccine 24: 1880-1888.
53. Krug, A., S. Rothenfusser, S. Selinger, C. Bock, M. Kerkmann, J. Battiany, A. Sarris, T. Giese, D. Speiser, S. Endres, and G. Hartmann. 2003. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 170: 3468-3477.
54. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3: 625-631.
55. Furumoto, K., L. Soares, E. G. Engleman, and M. Merad. 2004. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113: 774-783.